TSXV: RKV
Redefining Cancer Care
Rakovina Therapeutics Inc. (TSX-V: RKV) is leveraging cutting-edge AI platforms to compress drug discovery timelines from years to just months.
Download Investor Kit — It’s free
Learn More About Our Research
TOP UNDERVALUED BIOTECH STOCK
PROJECTED $18B ANNUAL MARKET
$5 MILLION RAISED IN 2024
PRE-CLINICAL DRUG DISCOVERY
IN PARTNERSHIP WITH UBC
HEADQUARTERS IN CANADA
WHAT WE DO
Rakovina (TSX-V: RKV) screens billions of compounds at 100x speed, facilitating accelerated progression to clinical development.
Our Vision
Our mission is to deliver hope to patients and families by creating therapies that extend lives, improve outcomes, and redefine possibilities in cancer treatment.
Unique Opportunity
Recent preclinical deals, such as the $1.5B Artios - Novartis and the $1.2B Remix - Sanofi deals, highlight the immense value Rakovina could unlock.
Advanced Technology: Rakovina (TSX-V: RKV) combines AI-driven innovation with a proven track record of success
World-Class Expertise: Advisory board member Dr. Artem Cherkasov, PhD — UBC professor and pioneer of the Deep Docking platform—has driven multiple successful drug licensing deals with major pharmaceutical companies
Download Investor Kit — It’s free
AI-Driven Drug Discovery
Deep Docking and Variational AI Enki are distinct computational modeling techniques to rapidly evaluate billions of compounds to identify novel therapeutic drug candidates.
Deep Docking delivers a 6,000x enrichment in drug candidate identification, cutting discovery timelines by up to 100x
Variational AI Enki creates entirely new chemical structures optimized for biological targets, accelerating drug development
Building on the foundation of the first-generation Deep Docking system, which identified a compound licensed to Roche in a $142M deal — the largest in University of British Columbia's (UBC) history
The second-generation system now powers Rakovina’s accelerated discovery process
Screened COVID-19 compounds in just
Rapid Progression to Preclinical and Clinical Development
Rakovina's pipeline includes three series targeting DNA-Damage Response (DDR) mechanisms.
The kt-3000 series features a preclinical candidate advancing through development to address hard-to-treat cancers such as breast, ovarian, and prostate
The kt-2000 & kt-5000 series are in discovery stages, with compounds being optimized to identify lead candidates
Access to UBC’s state-of-the-art wet-lab facilities accelerating the validation of AI-identified compounds
Experienced management and advisory teams with a proven track record of advancing innovative cancer therapies from discovery to commercialization.
Artem Cherkasov, PhD, the creator of Deep Docking with 200+ papers and 8 licensed drugs expertise
Petra Hamerlik, PhD, a former AstraZeneca DDR program director, bringing world-class DDR expertise
Download Investor Kit — It’s free
Unique Opportunity
Deep Docking revolutionizes drug discovery by evaluating billions of compounds to identify the most promising candidates.
Benefits
High-Yield Discovery: Rapidly screens extensive chemical libraries to pinpoint top candidates
Accelerated Timelines: Reduces the discovery phase from years to months, significantly lowering costs
Maximized Success Rates: Predicts safety and efficacy with exceptional precision
enrichment in drug candidates identification
speed of drug candidates discovery
By combining Deep Docking with Variational AI’s generative capabilities, we expand our pipeline faster and more effectively than ever before.
Innovative Molecule Optimization
Screen Billions of Compounds in Record Time
Recent
Milestones
Successfully raised $5 million in 2024 to advance preclinical developments.
Partnerships with UBC, Dr. Artem Cherkasov, and Variational AI accelerate discovery efforts.
Named among the Top Undervalued Biotech Stocks on the TSX Venture Exchange.
Meet Our Leadership
At Rakovina Therapeutics, innovation is driven by a team of experts in oncology, biotechnology, and drug discovery.
Executive Team
Jeffrey Bacha, BSc, MBA
Executive Chairman
Over 25 years of leadership in biotech innovation
Mads Daugaard, PhD
President & CSO
Renowned expert in DNA-damage response mechanisms
John Langlands, PhD
COO
A proven track record in advancing therapeutic pipelines
Scientific Advisory Board
Artem Cherkasov, PhD
AI & Medicinal Chemistry Advisor
Creator of the Deep Docking™ AI Platform
Petra Hamerlik, PhD
DDR Program Advisor
Former head of DDR programs at AstraZeneca
Download Investor Kit — It’s free